Get started
Novo Nordisk A/S Class BNovo Nordisk A/S Class BNovo Nordisk A/S Class B

Novo Nordisk A/S Class B

No trades
OverviewFinancialsNewsIdeasMindsTechnicalsForecastsSeasonalsBondsETFs

Market insights

$NVO Quality GIGA-LONNNNNNNGGGGG!!!This is a weekly of NVO, a global leader in pharmaceuticals addressing issues like obesity, diabetes, among other things. Ever hear of Ozempic? This company makes it. They also have other products in their pipeline which intend to capitalize on these growing epidemics, such as the recently approve ORAL version of Wegovy, a successful GLP-1 agonist. Anyway, back to the chart...You see a head and shoulders reversal at the top (red arcs); price then started forming a bear channel and remained in one for over a year; bear channels are bull flags, so the odds are that we get a bullish continuation once price breaks out to the upside; you see capitulation volume on the large bear weekly candle from July 28 of this year; then notice the retest of that level, forming a double-bottom (green arcs) on the weekly candle of Nov 24; the retest was on much lower volume, indicating supply has dried up, and price is ready for a move higher; Also, note the bullish MACD divergence on the lower pane (green upsloping line) as yet another CONFLUENCE (I hate that word); The Volume by Price indicator (horizontal lines to the left) shows a lot os support at the current levels as indicated by the proportion of green (buying) to grey (selling); I believe price will rotate higher and ultimately test the top of the head and shoulders from whence it came, implying a nearly 3X in price... This is one I would buy in a long-term account and let it marinate. An interesting combination value play AND growth play. Stop loss would be placed below the 2nd double-bottom at about $42...Take profit is $141. DO NOT TAKE THIS TRADE!!! DO NOT FOLLOW MY ADVICE!!! (DISCALIMER)....Merry Christmas from MrJosephTrades. Happy New Year as well...
NYSE:NVOLong
by MrJosephTrades
5
Novo Nordisk (NVO) 1WI’m looking at the weekly NVO chart as of late December 2025, and this is no longer about fear or headlines. It’s about structure and valuation. After a powerful multi year rally from 2022 to 2024, the stock went through a deep and healthy correction. In 2025, price built a strong weekly demand base around the 50–55 USD area, where volume profile, historical support and long term buyers align. Selling pressure is fading, volatility is compressing, and price action is stabilizing. Technically, NVO is transitioning into a post correction accumulation phase. On the weekly timeframe, RSI has recovered from oversold territory and is holding a neutral bullish range. MACD is forming a constructive reversal structure, while declining volume on down moves suggests exhaustion rather than distribution. As long as price holds the weekly base and does not break lower, the recovery scenario remains valid, with upside reference zones near 72–75 USD and later 90–92 USD if momentum confirms. From a fundamental perspective, as of the end of 2025, Novo Nordisk remains one of the highest quality businesses in global healthcare. Revenue exceeds 39 billion USD, with the Diabetes and Obesity Care segment generating more than 85% of total sales, continuing to show resilient growth. The United States and Europe remain the core revenue drivers, while international markets continue to expand steadily. Cash flow quality remains strong. Operating cash flow is above 18 billion USD on a TTM basis, free cash flow stays positive despite heavy investments into capacity expansion and R&D. Dividend policy remains disciplined and shareholder friendly, with TTM dividend yield around 2.3% and a payout ratio near 35–36%, leaving room for both reinvestment and future dividend growth. What matters is that the 2025 correction did not come with any structural deterioration of the business. This was not a business breakdown, but a valuation reset after an extreme growth phase. Expectations have been normalized, multiples compressed, while fundamentals stayed intact. That’s where asymmetry begins to emerge. Tactically, I see NVO as a long term quality compounder, where 2025 served as a reset year. As long as the weekly structure holds, the path for gradual upside remains open. This is not a short term trade, but a trend rebuilding phase driven by cash flow, market leadership and scale. Sometimes the best opportunities appear not at peak optimism, but when the market has already done its emotional damage and the numbers are still standing.
NYSE:NVOLong
by TotoshkaTrades
7
NVO – Weekly Structure UpdateThesis NVO is attempting a structural reversal after a deep corrective phase, supported by both long-term trend support and improving fundamental visibility. Context - Weekly timeframe - 70% correction from cycle highs - Price has respected the long-term trendline originating in 2016 - Recent product developments in weight-loss therapies improve long-term business outlook What I see - Price held the long-term rising support after the correction - Recent advance reclaimed the 50-day moving average - Price is consolidating above short-term support, suggesting stabilization - Structure is transitioning from decline to base formation What matters now - Holding above the 50-day MA keeps the early reversal structure intact - Next key test sits at the confluence of the 0.618 Fibonacci retracement and the 200-day moving average near the $60 area Buy / Accumulation zone - Pullbacks toward the current base and rising support zone remain the area of interest Targets - Initial resistance at the 0.618 Fib / 200-day MA confluence - A confirmed higher low after that test would define Wave 1–2 structure - Longer-term reference remains the 200-week moving average overhead Risk / Invalidation - Loss of the long-term trendline would invalidate the reversal thesis
NYSE:NVOLong
by maratteo
Breaking: Novo Nordisk A/S (NVO) Set For 80% BreakoutShares in Novo Nordisk surged over 7% Tuesday premarket after the Wegovy maker secured approval of its GLP-1 pill — a world first. The U.S. Food and Drug Administration’s approval of Novo Nordisk’s GLP-1 pill gives the Danish pharmaceutical giant a head start over U.S. rival Eli Lilly The pill’s starting dose of 1.5 milligrams will be available in pharmacies and via select telehealth providers with savings offers for $149 per month in early January, the firm said. Cash-paying patients can access it for the same price via President Donald Trump’s direct-to-consumer website, TrumpRx, according to the deal Novo Nordisk struck with his administration last month. Drug pricing has been top of mind this year as the U.S. looks to reduce the costs paid by consumers. The approval caps a turbulent year for Novo, which has been marked by board drama, supply chain shortages, a bidding war against Pfizer, and criticisms over the execution of its U.S. strategy. Technically, NYSE:NVO stock is gearing for a 80% breakout as the asset is set to break above the symmetrical triangle pattern amidst the FDA approval news bid. About NVO Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
NYSE:NVOLong
by DEXWireNews
$NVO - Novo Nordisk Has Taken a Beating 2025Novo Nordisk’s bullish scenario centers on sustained global demand for its GLP-1 franchise, with Wegovy and Ozempic expanding beyond diabetes into obesity, cardiovascular protection, and additional metabolic indications. Capacity expansions support multi-year volume growth, while emerging markets adoption accelerates. Pipeline assets, including next-generation oral GLP-1s and combination therapies, provide upside optionality and extend the company’s competitive moat. Margins remain strong due to scale advantages and high pricing power, driving robust free-cash-flow growth and rising returns on capital. In this scenario, Novo continues compounding earnings at a high single- to low double-digit rate, pushing intrinsic value meaningfully above current levels and supporting further share appreciation. Keeping an eye on this one around these levels. Disclaimer: I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor. All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies. I will not and cannot be held liable for any actions you take as a result of anything you read here. Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on here, expressed or implied herein, are committed at your own risk, financial or otherwise. Feel free to give us a follow and shoot us a like for more analysis updates.
NYSE:NVOLong
by MannyLo
NVO long-term TAThere's a good chance that Novo Nordisk will shine again! Technically speaking the volumes and the indicators have not turned bullish yet, but despite of the long downtrend the indicators have been improving for quite some time, weekly accumulation is rising steadily, which signals positive divergence, the current area of $40-45 is good for the support and potential new uptrend in the process. Can it dive even lower? Sure it can but that will push the divergence even higher. In short, keep an eye on NVO.
NYSE:NVO
by MoxGo_Analytics
Novo Nordisk $NVO – Undercut and Reverse Setup AnalysisTrade Setup Overview Novo Nordisk (NVO) is currently exhibiting characteristics of a classic undercut and reverse chart pattern. On November 24th, there was a distinct sign of lower price rejection, indicating that institutional buyers were active in the market. This activity was marked by a significant increase in trading volume, resulting in a pocket pivot, which is often considered a bullish signal. Technical Developments As of today, NVO has reclaimed its position above the 21-day exponential moving average (EMA). The stock now appears poised to break out above its established flat base. In response to these technical indicators, I have decided to take a full position in the stock, anticipating a potential breakout. Risk Management To manage downside risk, I have set my stop loss at a close below the low reached on November 25th. This stop placement represents approximately a 6.5% loss from my entry point. While this stop-loss is somewhat larger than my usual preference, it remains within my acceptable risk management range. Investment Considerations It is important for readers to conduct their own analysis and adhere to their personal trading strategies. All investments inherently involve risk, and making informed decisions is essential when allocating capital in the financial markets.
NYSE:NVOLong
by Brent_Calver
3
Novo Nordisk: The European Giant Challenging Alphabet Novo Nordisk: The European Giant Challenging Alphabet in the Debt Market By Ion Jauregui – Analyst at ActivTrades The European corporate debt market closes 2025 with a surprise: Alphabet becomes the largest issuer of euro-denominated bonds of the year, with €13.25 billion placed and 3.1% of the total issued volume. However, the Danish company Novo Nordisk, Europe’s capitalization leader, positions itself as its main competitor, with €12.7 billion in issuances. Interest in both companies reflects the search for defensive and growth assets, but in the case of Novo Nordisk, the fundamentals provide unmatched strength. Fundamentals: Solid Growth and Structural Demand Novo Nordisk continues to expand, driven by its flagship drugs for diabetes and obesity (Ozempic and Wegovy), consolidating a business model with exceptional margins. • Annual growth: over 20% • Operating margin: above 44% • Solid cash position: even after investments in production capacity • Future market: obesity could exceed 1 billion global patients by 2030 The biopharmaceutical company does not issue debt out of necessity, but to finance industrial expansions and capture a rapidly growing healthcare market. The Debate: Bubble in the Debt Market? The rise in European issuances, especially from technology and pharmaceutical companies, has led some fund managers to warn of a possible bubble due to concentration rather than valuation. Unlike other issuers, Novo Nordisk maintains solid fundamentals that justify demand for its bonds, placing it among the safest issuers in Europe. Technical Analysis: Consolidation with Bullish Bias Since its all-time highs in June 2024, when it reached €134.14, the company’s stock corrected to a low in August 2025 around €38.09. This Monday, the price showed a technical rebound, closing yesterday at €42 after a week of bullish performance. If the price manages to retake the previous consolidation range, between €53.46 and €61.11, we could anticipate a more significant advance. For now, the stock is near the €42.5 consolidation zone, coinciding with the point of control (POC), a key accumulation and support level. Technical indicators show mixed signals: the RSI is recovering at 45.06%, while the MACD confirms a positive evolution with the histogram in positive territory. However, the moving average crossover does not yet fully support the bullish trend: the price remains around the 50-day moving average, while the 100- and 200-day moving averages are still sloping downward. In terms of scenarios, if the price fails to hold the annual low, we could see a bearish continuation toward €30. Conversely, if the support, which has been tested three times, holds, a clear upward rebound is possible. According to ActivTrades Europe Market Pulse, market sentiment shows a risk-on bias, although the overall situation remains neutral for now, reflecting caution among investors. European Benchmark Novo Nordisk confirms its position as one of the most solid European benchmarks, both in the debt and equity markets. Its structural growth, sustained demand for its treatments, and financial discipline distinguish it from competitors such as Alphabet and Volkswagen. Although technical analysis shows critical support levels that will condition the next price movement, the stock maintains a bullish recovery bias, supported by positive indicators and a market still favorable to controlled risk. Overall, Novo Nordisk combines stability and growth potential, consolidating itself as a defensive and strategic investment for investors seeking exposure to a leading European biopharmaceutical company. ******************************************************************************************* The information provided does not constitute investment research. The material has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and such should be considered a marketing communication. All information has been prepared by ActivTrades ("AT"). The information does not contain a record of AT's prices, or an offer of or solicitation for a transaction in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. Any material provided does not have regard to the specific investment objective and financial situation of any person who may receive it. Past performance and forecasting are not a synonym of a reliable indicator of future performance. AT provides an execution-only service. Consequently, any person acting on the information provided does so at their own risk. Political risk is unpredictable. Central bank actions can vary. Platform tools do not guarantee success.
XETR:NOV
by ActivTrades